144 related articles for article (PubMed ID: 29260621)
21. Therapeutic approaches to inflammation in neurodegenerative disease.
Klegeris A; McGeer EG; McGeer PL
Curr Opin Neurol; 2007 Jun; 20(3):351-7. PubMed ID: 17495632
[TBL] [Abstract][Full Text] [Related]
22. Immune receptor for pathogenic α-synuclein.
Jucker M; Heikenwalder M
Science; 2016 Sep; 353(6307):1498-1499. PubMed ID: 27708090
[No Abstract] [Full Text] [Related]
23. Combination therapies: The next logical Step for the treatment of synucleinopathies?
Valera E; Masliah E
Mov Disord; 2016 Feb; 31(2):225-34. PubMed ID: 26388203
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.
Fagerqvist T; Lindström V; Nordström E; Lord A; Tucker SM; Su X; Sahlin C; Kasrayan A; Andersson J; Welander H; Näsström T; Holmquist M; Schell H; Kahle PJ; Kalimo H; Möller C; Gellerfors P; Lannfelt L; Bergström J; Ingelsson M
J Neurochem; 2013 Jul; 126(1):131-44. PubMed ID: 23363402
[TBL] [Abstract][Full Text] [Related]
25. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease.
Giasson BI; Jakes R; Goedert M; Duda JE; Leight S; Trojanowski JQ; Lee VM
J Neurosci Res; 2000 Feb; 59(4):528-33. PubMed ID: 10679792
[TBL] [Abstract][Full Text] [Related]
26. Active immunization therapies for Parkinson's disease and multiple system atrophy.
Schneeberger A; Tierney L; Mandler M
Mov Disord; 2016 Feb; 31(2):214-24. PubMed ID: 26260853
[TBL] [Abstract][Full Text] [Related]
27. Innate immunity regulates α-synuclein clearance.
Sawamura M; Uemura N; Takahashi R
Mov Disord; 2016 May; 31(5):638. PubMed ID: 26946483
[No Abstract] [Full Text] [Related]
28. Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.
Horvath I; Iashchishyn IA; Forsgren L; Morozova-Roche LA
ACS Chem Neurosci; 2017 Jun; 8(6):1170-1176. PubMed ID: 28263550
[TBL] [Abstract][Full Text] [Related]
29. Pathogenesis-targeted therapeutic strategies in Parkinson's disease.
Jankovic J
Mov Disord; 2019 Jan; 34(1):41-44. PubMed ID: 30484897
[No Abstract] [Full Text] [Related]
30. Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.
Gerson JE; Farmer KM; Henson N; Castillo-Carranza DL; Carretero Murillo M; Sengupta U; Barrett A; Kayed R
Mol Neurodegener; 2018 Mar; 13(1):13. PubMed ID: 29544548
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy trials in Parkinson's disease: challenges.
Xiao B; Tan EK
J Transl Med; 2023 Mar; 21(1):178. PubMed ID: 36879300
[No Abstract] [Full Text] [Related]
32. α-Synuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa.
Skorvanek M; Gelpi E; Mechirova E; Ladomirjakova Z; Han V; Lesko N; Feketeova E; Repkova B; Urbancikova Z; Vargova A; Spisak P; Ribeiro Ventosa J; Kudela F; Kulcsarova K; Babinska S; Toth S; Gombosova L; Zakuciova M; Veseliny E; Trebuna F; Lutz MI; Gdovinova Z; Kovacs GG;
Mov Disord; 2018 Aug; 33(8):1366-1368. PubMed ID: 30230627
[No Abstract] [Full Text] [Related]
33. Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.
Gelders G; Baekelandt V; Van der Perren A
J Immunol Res; 2018; 2018():4784268. PubMed ID: 29850629
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticle standards for immuno-based quantitation of α-synuclein oligomers in diagnostics of Parkinson's disease and other synucleinopathies.
Herrmann Y; Bujnicki T; Zafiu C; Kulawik A; Kühbach K; Peters L; Fabig J; Willbold J; Bannach O; Willbold D
Clin Chim Acta; 2017 Mar; 466():152-159. PubMed ID: 28088342
[TBL] [Abstract][Full Text] [Related]
35. Novel antibodies to phosphorylated α-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes.
Rutherford NJ; Brooks M; Giasson BI
Acta Neuropathol Commun; 2016 Aug; 4(1):80. PubMed ID: 27503460
[TBL] [Abstract][Full Text] [Related]
36. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
Vekrellis K; Stefanis L
Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.
Olson KE; Gendelman HE
Curr Opin Pharmacol; 2016 Feb; 26():87-95. PubMed ID: 26571205
[TBL] [Abstract][Full Text] [Related]
38. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
[TBL] [Abstract][Full Text] [Related]
39. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W; Schulz JB
J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
[TBL] [Abstract][Full Text] [Related]
40. α-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model.
Sanchez-Guajardo V; Annibali A; Jensen PH; Romero-Ramos M
J Neuropathol Exp Neurol; 2013 Jul; 72(7):624-45. PubMed ID: 23771222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
